FDA warns Avila Herbals and investigator over drug trial lacking required FDA application, ethics review, and consent.
What happened
FDA inspected the clinical site from July 12 to July 26, 2021, and reviewed Avila Herbals as sponsor and Dr. Obiso as clinical investigator. FDA found that a human study of an investigational drug began without an IND (an FDA application required before human testing), without review by an IRB (an ethics review board that meets FDA rules), without an IRB-approved written consent form, and without drug disposition records for subjects who received the drug.
What FDA found
The company began a human study of an investigational drug without an IND (an FDA application required before human testing).
21 CFR 312.20(a), 312.20(b), and 312.40(a)The investigator did not ensure that an IRB (an ethics review board that meets FDA rules) reviewed and approved the study before it began.
21 CFR 312.66The investigator did not document informed consent with a written consent form approved by the IRB.
21 CFR 312.60 and 21 CFR 50.27(a)The investigator did not keep drug disposition records showing dates, quantity, and use by subjects.
21 CFR 312.62(a)
What FDA wants
FDA tells Dr. Obiso and Avila Herbals to respond in writing within 15 business days with the actions taken to prevent similar violations and to address the deficiencies; failure to do so may lead to regulatory action.
Who should pay attention
- clinical investigators running early-phase drug studies
- sponsors of botanical or other nonapproved product trials
- IRBs and research compliance teams
This is a summary. Read the original letter on fda.gov.